Products
Toremifene is commercially available in tablet form (Fareston). It was approved in many countries in 1996 and went off the market in 2012.
Structure and properties
Toremifene (C26H28ClNO, 405.96 g/mol)
Effects
Toremifene (ATC L02BA02) is antiestrogenic.
Indications
Local unresectable, locally recurrent, or metastatic postmenopausal breast carcinoma (breast cancer).
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common adverse effects are hot flashes. Increased sweating, nausea, and leukorrhea are common.
